Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797352 | 0.92 | SSTR4 (0.42) | MCHR1SSTR5SSTR3SSTR2SSTR1 | |
| SCHEMBL2797350 | 0.92 | SSTR4 (0.42) | MCHR1SSTR5SSTR3SSTR2SSTR1 | |
| SCHEMBL25412287 | 0.90 | SLC6A2 (0.43) | MCHR1SSTR5SSTR3SSTR2SSTR1 | |
| SCHEMBL25412293 | 0.90 | SLC6A2 (0.43) | MCHR1SSTR5SSTR3SSTR2SSTR1 | |
| SCHEMBL25414374 | 0.87 | LMNA (0.34) | MCHR1SSTR5SSTR3 | |
| SCHEMBL7144653 | 0.85 | TLR4 (0.36) | MCHR1SSTR5SSTR3SSTR2 | |
| SCHEMBL13231369 | 0.85 | TACR2 (0.39) | MCHR1SSTR5SSTR3SSTR2SSTR1 | |
| SCHEMBL2798128 | 0.85 | TACR2 (0.39) | MCHR1SSTR5SSTR3SSTR2SSTR1 | |
| SCHEMBL2798123 | 0.85 | TACR2 (0.39) | MCHR1SSTR5SSTR3SSTR2SSTR1 | |
| SCHEMBL7136889 | 0.82 | SLC5A1 (0.36) | MCHR1SSTR5SSTR3SSTR2SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002425-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-01-04 | — | — | US | disclosed |
| EP-4245763-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002425-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | TLR4, TLR5, TLR9 | MCHR1 3247/4885SSTR5 2455/4885SSTR3 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.